The stock of Tempest Therapeutics Inc (TPST) has seen a 6.73% increase in the past week, with a -4.12% drop in the past month, and a -11.42% decrease in the past quarter. The volatility ratio for the week is 5.87%, and the volatility levels for the past 30 days are at 11.89% for TPST. The simple moving average for the past 20 days is -9.49% for TPST’s stock, with a 21.66% simple moving average for the past 200 days.
Is It Worth Investing in Tempest Therapeutics Inc (NASDAQ: TPST) Right Now?
The 36-month beta value for TPST is also noteworthy at -1.63. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TPST is 16.76M, and at present, short sellers hold a 5.79% of that float. The average trading volume of TPST on April 24, 2024 was 984.95K shares.
TPST) stock’s latest price update
The stock price of Tempest Therapeutics Inc (NASDAQ: TPST) has jumped by 2.05 compared to previous close of 3.42. Despite this, the company has seen a gain of 6.73% in its stock price over the last five trading days. Seeking Alpha reported 2024-04-17 that Tempest Therapeutics, Inc. achieved positive results from phase 1b/2 study using TPST-1120 + Tecentriq + Avastin for the treatment of patients with 1st-line HCC; Significant improvements in both confirmed and unconfirmed responses. Updated results from the phase 1b/2 study, using TPST-1120 + Tecentriq + Avastin for the treatment of patients with 1st-line HCC, are expected in 2024. It is expected that the global liver cancer drug market size is expected to reach $7.6 billion by 2033.
Analysts’ Opinion of TPST
Many brokerage firms have already submitted their reports for TPST stocks, with Scotiabank repeating the rating for TPST by listing it as a “Sector Outperform.” The predicted price for TPST in the upcoming period, according to Scotiabank is $13 based on the research report published on March 14, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see TPST reach a price target of $15. The rating they have provided for TPST stocks is “Buy” according to the report published on February 08th, 2024.
TPST Trading at -7.05% from the 50-Day Moving Average
After a stumble in the market that brought TPST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.28% of loss for the given period.
Volatility was left at 11.89%, however, over the last 30 days, the volatility rate increased by 5.87%, as shares sank -5.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.98% lower at present.
During the last 5 trading sessions, TPST rose by +7.03%, which changed the moving average for the period of 200-days by +207.02% in comparison to the 20-day moving average, which settled at $3.85. In addition, Tempest Therapeutics Inc saw -20.68% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TPST
The total capital return value is set at -0.69. Equity return is now at value -131.42, with -60.38 for asset returns.
Based on Tempest Therapeutics Inc (TPST), the company’s capital structure generated 0.3 points at debt to capital in total, while cash flow to debt ratio is standing at -2.38. The debt to equity ratio resting at 0.43. The interest coverage ratio of the stock is -41.48.
Currently, EBITDA for the company is -28.78 million with net debt to EBITDA at 0.65. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.29.
Conclusion
In summary, Tempest Therapeutics Inc (TPST) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
